Author:
Chan Kelley,Chauhan Aman,Shi Chanjuan
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Chauhan A, Chan K, Halfdanarson TR, et al. Critical updates in neuroendocrine tumors: version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2024. https://doi.org/10.3322/caac.21840.
2. Klimstra DS, Kloppel G, La Rosa S, et al. Classification of neuroendocrine neoplasms of the digestive system. In: WHO classification of tumours editorial board, editors. Digestive System tumours: WHO classification of tumours. 5th ed. International Agency for Research on Cancer; 2019:16–22
3. Del Rivero J, Mailman J, Rabow MW, et al. Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care. Endocr Relat Cancer. 2023;30(7):e220226. https://doi.org/10.1530/ERC-22-0226.
4. Ge PS, Shi C, Asare E, Washington MK, O’Toole D. Expanding role of gastroenterology in the staging of digestive neuroendocrine tumors: updates from the AJCC version 9 cancer staging system. Clin Gastroenterol Hepatol. 2023;22(3):448–451. https://doi.org/10.1016/j.cgh.2023.10.033.
5. Rais R, Trikalinos NA, Liu J, Chatterjee D. Enterochromaffin-like cell hyperplasia-associated gastric neuroendocrine tumors may arise in the setting of proton pump inhibitor use. Arch Pathol Lab Med. 2022;146:366–71. https://doi.org/10.5858/arpa.2020-0315-OA.